Latest Radioimmunotherapy Stories

NEW YORK, Jan. 28, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, (OTC BB: CTVN), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, reported today that the program of the EMIT: Targeted Radiotherapy conference will feature three presentations devoted to Actinium Pharmaceuticals' clinical programs and technology platform. These presentations will address broadening use of radiolabeled monoclonal antibodies for Hematopoietic Stem Cell...

NEW YORK, Dec. 26, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc., a leader in the field of alpha radioimmunotherapy for treatment of advanced cancers, is pleased to announce that it has successfully completed a first closing of $5.1 million in its current round of financing, for which Laidlaw & Company (UK) Ltd. is exclusive placement agent. Funding will be used primarily for further development of Actimab?A, Actinium's lead drug candidate in multicenter Phase I/II trials...

NEW YORK, Nov. 27, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. will sponsor a webinar on the "Promise of Alpha Therapy". The discussion will be broadcast and can be accessed via the link http://www.veomed.com/grandrounds?gnr=871099 on November 30, 2012 at 3:00 PM and followed by questions and answers session from the audience. Participants will discuss their personal experience, both clinical and pre-clinical, with alpha particle immunotherapy platform-based drug...

NEW YORK, Oct. 24, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc., (API), a private biopharmaceutical company that develops innovative targeted radio-immunotherapeutics, announced that the poster summarizing the results for Phase I study of Actimab-A, its antibody directed alpha emitter drug candidate, has won a first place poster presentation award at the 8th Annual Hematologic Malignancies 2012 Conference held in Houston, TX, from October 10-14. The award was presented to...

NEW YORK, Sept. 7, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that the Company is moving forward with enrollment and treatment of additional patients in its clinical trial for acute myeloid leukemia (AML) in patients over the age of 60. Actinium will proceed with patient screening and enrollment for the second cohort, who, in keeping with trial protocol, will be...

Study shows a cancer therapy for renal cell carcinoma patients may be affected by another anti-cancer drug Research revealed at the Society of Nuclear Medicine's 2012 Annual Meeting explores treatment with a newly developed type of radioimmunotherapy used for treating a resistant form of kidney cancer. The agent is able to hone in on the disease, called clear cell renal carcinoma, and kill the cancer by delivering radiation directly to it. However, the study shows that its effectiveness...

Actinium Pharmaceuticals, Inc., a leader in the field of cancer alpha radioimmunotherapy, successfully completed a first closing of $4.1 million in its Series E Financing, for which Laidlaw & Company (UK) Ltd. is exclusive placement agent. Newark, NJ (PRWEB) October 12, 2011 Actinium Pharmaceuticals, Inc., a leader in the field of alpha radioimmunotherapy for treatment of advanced cancers, is pleased to announce that it has successfully completed a first closing of $4.1 million in its...

AREVA announced that its subsidiary AREVA Med has started a Phase 1 clinical trial for its lead product ²¹²Pb-TCMC-Trastuzumab in patients with HER-2 positive intra-abdominal cancers. Bethesda, MD (PRWEB) August 04, 2011 AREVA announced that its subsidiary AREVA Med has started a Phase 1 clinical trial for its lead product ²¹²Pb-TCMC-Trastuzumab in patients with HER-2 positive intra-abdominal cancers. The new trial (AREVAMED01) is an open label Phase 1, dose...

(Ivanhoe Newswire) -- About 50,000 Americans are diagnosed with kidney cancer every year, but a new form of radioimmuntherapy may decrease this number significantly.Radioimmunotherapy zeroes in on antigens associated with kidney cancer cells. Patients with progressive kidney cancer receiving as much as three times the dosage show dramatic slowing of cancer growth and stabilization of their disease."This study is another step forward in developing a cancer therapy that has the potential...

(Ivanhoe Newswire) "“ Colorectal cancer is the third most commonly diagnosed cancer in the Unites States, and the third leading cause of cancer death. It develops in the colon and rectum, usually as a result of polyps, which are abnormal growths of tissue that extend from mucous membranes in the lower gastrointestinal tract. The most common treatments for this cancer are surgery and chemotherapy. However, chemotherapy can have many life threatening side effects.Now researchers from...